FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Biologics

Kessler Praises Marks on Covid Response Leadership

CBER director Peter Marks gets high grades from former FDA commissioner and Biden administration Covid chief science officer David Kessler on Marks le...

latest-news-card-1
Marketing

Lower Added Benefit Associated with Higher DTC Spend

Johns Hopkins University researchers say spending on direct-to-consumer ads in 2020 was associated with drugs rated with lower added clinical benefit ...

latest-news-card-1
Human Drugs

Court Throws Out PhRMA Lawsuit on Drug Importation

The DC District Court dismisses for lack of standing a Pharmaceutical Research and Manufacturers of America-led lawsuit that sought to block HHS and F...

latest-news-card-1
Human Drugs

Roche Data on Crovalimab Met Primary Endpoints

A Roche Phase 3 study called COMMODORE 2 that was evaluating the efficacy and safety of crovalimab in certain people with paroxysmal nocturnal hemoglo...

latest-news-card-1
Human Drugs

FDA Offers Advisory Committee Hearing on Intarcia Dispute

FDA proposes an advisory committee-led hearing to address a CDER 2021 decision not to approve an NDA submitted by Intarcia Therapeutics for ITCA 650 (...

latest-news-card-1
Medical Devices

MicroVention Costa Rica Has QS Issues

FDA warns Alajuela, Costa Rica-based MicroVention Costa Rica about Quality System regulation violations in the manufacture of microcatheters and ballo...

latest-news-card-1
Medical Devices

FDA Urges Reporting of Home Covid Test Results

FDA revises its online guide on when and how often people should use an over-the-counter at-home Covid-19 test to encourage users to self-report their...

latest-news-card-1
Biologics

Takeda sBLA for Takhzyro Expanded Indication

FDA approves a Takeda supplemental BLA for an expanded use of Takhzyro (lanadelumab-flyo) prophylaxis to prevent attacks of hereditary angioedema in ...

latest-news-card-1
Federal Register

Determinations on 31 Drugs Available for ANDAs

Federal Register notice: FDA determines that 31 drug products were not withdrawn from sale due to safety or effectiveness reasons.

latest-news-card-1
Human Drugs

Rapid-Acting Depression Drug Gets Priority Review

FDA accepts for priority review a Biogen and Sage Therapeutics, NDA for zuranolone, a rapid-acting once daily oral drug for major depressive disorder ...